Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial

被引：42
|
作者：
Schneider, LS [1 ]
Ismail, MS [1 ]
Dagerman, K [1 ]
Davis, S [1 ]
Olin, J [1 ]
McManus, D [1 ]
Pfeiffer, E [1 ]
Ryan, JM [1 ]
Sultzer, DL [1 ]
Tariot, PN [1 ]
机构：
[1] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
来源：
SCHIZOPHRENIA BULLETIN | 2003年 / 29卷 / 01期
关键词：
Alzheimer's disease; atypical antipsychotic; psychosis; dementia; effectiveness;
D O I：
10.1093/oxfordjournals.schbul.a006991
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
This article describes the development of the protocol for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Alzheimer's disease trial, which was developed in collaboration with the National Institute of Mental Health to assess the effectiveness of atypical antipsychotics for psychosis and/or agitation occurring in outpatients with Alzheimer's disease. The article provides a detailed description of the methodology used in the trial as well as the clinical outcomes and effectiveness measures incorporated into it, discussing the most salient issues encountered in developing the design of the trial, as well as the unique features of the trial.
引用
收藏
页码：57 / 72
页数：16
相关论文
共 50 条
  • [31] Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial
    Beaudoin, Melissa
    Hudon, Alexandre
    Giguere, Charles-Edouard
    Potvin, Stephane
    Dumais, Alexandre
    SCHIZOPHRENIA, 2022, 8 (01)
  • [32] Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies
    Volavka, J.
    Van Dorn, R. A.
    Citrome, L.
    Kahn, R. S.
    Fleischhacker, W. W.
    Czobor, P.
    EUROPEAN PSYCHIATRY, 2016, 31 (01) : 13 - 19
  • [33] The Impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on Prescribing Practices: An Analysis of Data From a Large Midwestern State
    Berkowitz, Rachel L.
    Patel, Urvashi
    Ni, Quanhong
    Parks, Joseph J.
    Docherty, John P.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (04) : 498 - 503
  • [34] Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies
    Davis, SM
    Koch, GG
    Davis, CE
    LaVange, LM
    SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 73 - 80
  • [35] NIMH comparative effectiveness of antipsychotic medications in patients with Alzheimer's disease (CATIE-AD): A progess report
    Ismail, MS
    Schneider, L
    Dagerman, K
    Tariot, PN
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 165 - 165
  • [36] Effektivität atypischer Antipsychotika bei Patienten mit Alzheimer-DemenzCATIE-AD-Studie (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer’s Disease)
    H. Förstl
    Der Internist, 2007, 48 (6): : 642 - 644
  • [37] Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study
    Davis, Sonia M.
    Stroup, T. Scott
    Koch, Gary G.
    Davis, Clarence E.
    Rosenheck, Robert A.
    Lieberman, Jeffrey A.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2011, 3 (02): : 253 - 265
  • [38] Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
    Hermes, Eric D. A.
    Sokoloff, Daniel
    Stroup, T. Scott
    Rosenheck, Robert A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (04) : 526 - 532
  • [39] Association of 9-Hydroxy Risperidone Concentrations With Risk of Switching or Discontinuation in the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial
    Wessels, Alette M.
    Pollock, Bruce G.
    Anyama, Norbert G.
    Schneider, Lon S.
    Lieberman, Jeffrey A.
    Marder, Stephen R.
    Bies, Robert R.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (06) : 683 - 687
  • [40] The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data
    Ozzoude, Miracle
    Nakajima, Shinichiro
    Plitman, Eric
    Chung, Jun Ku
    Kim, Julia
    Iwata, Yusuke
    Caravaggio, Fernando
    Takeuchi, Hiroyoshi
    Uchida, Hiroyuki
    Graff-Guerrero, Ariel
    Gerretsen, Philip
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2019, 89 : 207 - 213
12345